Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor α

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1922-1928

  Moro, Monica ^a   Pelagi, Micaela ^a   Fulci, Giulia ^a   Paganelli, Giovanni ^b   Dellabona, Paolo ^a   Casorati, Giulia ^a   Siccardi, Antonio G ^c   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLYSIS; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; TUMOR CELL;

ANIMALS; ANTIBODIES; AVIDIN; BIOTIN; CYTOTOXICITY, IMMUNOLOGIC; IMMUNOCONJUGATES; IMMUNOTOXINS; LYMPHOMA; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030913971     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 72: 3666-3670, 1975.
2. Helson, L., Green, S., Carswell, E., and Old, L. J. Effect of tumor necrosis factor on cultured human melanoma cells. Nature (Lond.), 258: 731-732, 1975.
3. Fiers, W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett., 285: 199-212, 1991.
4. Sidhu, R. S., and Bollon, A. P. Tumor necrosis factor activities and cancer therapy: a perspective. Pharmacol. Ther., 57: 79-128, 1993.
5. Spriggs, D. R., and Yates, W. Cancer chemotherapy. Experiences with TNF administration in humans. In: B. Beutler (ed.). Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, pp. 383-406. New York: Raven Press, 1992.
6. Eck, M. J., and Sprang, S. R. The structure of tumor necrosis factor-α at 2.6 A resolution. Implications for receptor binding. J. Biol. Chem., 264: 17595-17605, 1989.
7. Jones, E. Y., Stuart, D. I., and Walker, N. P. C. Structure of tumor necrosis factor. Nature (Lond.), 338: 225-228, 1989.
8. Smith, R. A., and Baglioni, C. The active form of tumor necrosis factor is a trimer. J. Biol. Chem., 262: 6951-6954, 1987.
9. Corti, A., Fassina, G., Marcucci, F., Barbanti, E., and Cassani, G. Oligomeric TNF-α slowly converts to inactive forms at bioactive levels. Biochem. J., 284: 905-910, 1992.
10. Vandenabeele, P., Declercq, W., Beyaert, R., and Fiers, W. Two tumor necrosis factor receptors: structure and function. Trends Cell. Biol., 5: 392-399, 1995.
11. Lewis, M., Tartaglia, L. A. Lee, A., Bennet, L. G., Rice, G. R., Wong, G. H. W., Chen, E. Y., and Goeddel, D. V. Cloning and expression of cDNA for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. USA, 88: 2830-2834, 1991.
12. Fiers, W. Biologic therapy with TNF: preclinical studies. In: V. De Vita, S. Hellman, and S. Rosenberg (eds.), Biologic Therapy of Cancer: Principles and Practice, pp. 295-327. Philadelphia: J. B. Lippincott Co., 1995.
13. Van Ostade, X., Vandenabeele, P., Everaerdt, B., Loetscher, H., Gentz, R., Brockhaus, M., Lesslauer, W., Tavernier, J., Brouckaert, P., and Fiers, W. Human TNF mutants with selective activity on the p55 receptor. Nature (Lond.), 361: 266-269, 1993.
14. Hoogenboom, H. R., Volckaert, G., and Raus, J. C. Construction and expression of antibody-tumor necrosis factor fusion proteins. Mol. Immunol., 28: 1027-1037, 1991.
15. Hwu, P., and Rosenberg, S. A. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detect. Prev., 18: 43-50, 1994.
16. Lejeune, F., Lienard, D., Eggermont, A., Schraffordt Koops, H., Kroon, B., Gerain, J., Rosenkaimer, F., and Schmitz, P. Clinical experience with high-dose tumor necrosis factor α in regional therapy of advanced melanoma. Circ. Shock, 43: 191-197, 1994.
17. Lienard, D., Eggermont, A. M., Schraffordt Koops, H., Kroon, B. B., Rosenkaimer, F., Autier, P., and Lejeune, F. J. Isolated perfusion of the limb with high-dose tumour necrosis factor-α (TNF-α), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res., 4: 21-26, 1994.
18. Paganelli, G., Magnani, P., Siccardi, A., and Fazio, F. Clinical application of the avidin-biotin system for tumor targeting. In: D. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 239-253. Boca Raton, FL: CRC Press, 1995.
19. Paganelli, G., Grana, C., Chinol, M., De Cicco, C., Cremonesi, M., Tarditi, L., Franceschini, R., Zoboli, S., De Braud, F., and Siccardi, A. G. Antibody guided radiotherapy in malignant glioma patients with Y-90-biotin using a 3-step pretargeting approach. Advances in the application of monoclonal antibodies in clinical oncology. The Thirteenth International Hammersmith Conference, 27th-30th May 1996. p. 36. Chania, Greece, 1996.
20. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., Seccamani, E., Siccardi, A. G., and Fazio, F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res., 51: 5960-5966, 1991.
21. Modorati, G., Brancato, R., Paganelli, G., Magnani, P., Pavoni, R., and Fazio, F. Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. Br. J. Ophthalmol., 78: 19-23, 1994.
22. Colombo, P., Paganelli, G., Magnani, P., Songini, C., Fazio, F., and Faglia, G. Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine/neuroendocrine tumors. J. Endocr. Invest., 16: 841-843, 1993.
23. Espevik, T., and Nissen-Meyer, J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods, 95: 99-105, 1986.
24. Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H., Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B., and Goeddel, D. V. Human tumor necrosis factor: precursor, structure, expression and homology to lymphotoxin. Nature (Lond.), 321: 724-729, 1984.
25. Tartaglia, L. A., Pennica, D., and Goeddel, D. V. Ligand passing: the 75 kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55 kDa TNF receptor. J. Biol. Chem., 268: 18542-18548, 1993.
26. Green, N. Avidin and streptavidin. Methods Enzymol., 184: 51-67, 1990.
27. Nezlin, R. Internal movements in immunoglobulin molecules. Adv. Immunol., 48: 1-39, 1990.
28. Lin, L. S. The design and activities of TNF muteins. In: B. Beutler (ed.), Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, pp. 33-48. New York: Raven Press, 1992.
29. Poiesi, C., Albertini, A., Ghielmi, S., Cassani, G., and Corti, A. Kinetic analysis of TNF-α oligomer-monomer transition by surface plasmon resonance and immunochemical methods. Cytokine, 5: 539-545, 1993.
30. Alzani, R., Cozzi, E., Corti, A., Temponi, M., Trizio, D., Gigli, M., and Rizzo, V. Mechanism of suramin-induced deoligomerization of tumor necrosis factor α. Biochemistry, 34: 6344-6350, 1995.
31. Talmadge, J. E., Tribble, H. R., Pennington, R. W., Phillips, H., and Wiltrout, R. H. Immunomodulatory and immunotherapeutic properties of recombinant γ-interferon and recombinant tumor necrosis factor in mice. Cancer Res., 47: 2563-2570, 1987.
32. Beyaert, R., De Potter, C., Vanhaesebroeck, B., Van Roy, F., and Fiers, W. Induction of inflammatory cell infiltration and necrosis in normal mouse skin by the combined treatment of tumor necrosis factor and lithium chloride. Am. J. Pathol., 138: 727-739, 1991.
33. Palladino, M. A., Jr., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., Deleo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., Liggitt, D., and Patton, J. S. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol., 138: 4023-4032, 1987.
34. Havell, E. A., Fiers, W., and North, R. J. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med., 167: 1067-1085, 1988.
35. Sato, N., Goto, T., Haranaka, K., Satomi, N., Nariuchi, H., Mano-Hirano, Y., and Sawasaki, Y. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J. Natl. Cancer Inst., 76: 1113-1121, 1986.
36. Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., and Urushizaki, I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 48: 2179-2183, 1988.
37. Vanhaesebroeck, B., Mareel, M., Van Roy, F., Grooten, J., and Fiers, W. Expression of the tumor necrosis factor gene in tumor cells correlates with reduced tumorigenicity and reduced invasiveness in vivo. Cancer Res., 51: 2229-2238, 1991.
38. Yang, J., Raju, R., Sharma, R., and Xiang, J. A genetically engineered fusion protein M4/TNF with increased bifunctional activity refolded in the presence of protein disulfide isomerase. Hum. Antib. Hybrid., 6: 129-136, 1995.
39. Paganelli, G., Sidoli, A., Chinol, M., Corti, A., Maggiolo, M., Baroni, S., and Siccardi, A. G. Three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur. J. Nucl. Med., in press, 1997.
40. Robert, B., Mach, J. P., Mani, J. C., Ychou, M., Folli, S., Artus, J. C., and Pelegrin, A. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor α. Cancer Res., 56: 4758-4765, 1996.